{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:10:51Z","timestamp":1782151851784,"version":"3.54.5"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sj\u00f6gren\u2019s syndrome is a systemic autoimmune disease characterized by immune cells predominantly infiltrating the exocrine glands and frequently forming ectopic lymphoid structures. These structures drive a local functional immune response culminating in autoantibody production and tissue damage, associated with severe dryness of mucosal surfaces and salivary gland hypofunction. Cenerimod, a potent, selective and orally active sphingosine-1-phosphate receptor 1 modulator, inhibits the egress of lymphocytes into the circulation. Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sj\u00f6gren\u2019s syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cenerimod was administered in two established models of Sj\u00f6gren\u2019s syndrome; firstly, in an inducible acute viral sialadenitis model in C57BL\/6 mice, and, secondly, in the spontaneous chronic sialadenitis MRL\/lpr mouse model. The effects of cenerimod treatment were then evaluated by flow cytometry, immunohistochemistry, histopathology and immunoassays. Comparisons between groups were made using a Mann-Whitney test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the viral sialadenitis model, cenerimod treatment reduced salivary gland immune infiltrates, leading to the disaggregation of ectopic lymphoid structures, reduced salivary gland inflammation and preserved organ function. In the MRL\/lpr mouse model, cenerimod treatment decreased salivary gland inflammation and reduced T cells and proliferating plasma cells within salivary gland ectopic lymphoid structures, resulting in diminished disease-relevant autoantibodies within the salivary glands.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Taken together, these results suggest that cenerimod can reduce the overall autoimmune response and improve clinical parameters in the salivary glands in models of Sj\u00f6gren\u2019s syndrome and consequently may reduce histological and clinical parameters associated with the disease in patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02673-x","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T04:20:22Z","timestamp":1638159622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1186","volume":"23","author":[{"given":"Estelle","family":"Gerossier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Nayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Froidevaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Runser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Iannizzotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vezzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabin","family":"Pierlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mentzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-3423","authenticated-orcid":false,"given":"Marianne M.","family":"Martinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"issue":"1","key":"2673_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4049\/jimmunol.130.1.203","volume":"130","author":"TC Adamson 3rd","year":"1983","unstructured":"Adamson TC 3rd, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol. 1983;130(1):203\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"2673_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","volume":"14","author":"G Nocturne","year":"2018","unstructured":"Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjogren syndrome. Nat Rev Rheumatol. 2018;14(3):133\u201345.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2673_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","volume":"34","author":"MI Christodoulou","year":"2010","unstructured":"Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun. 2010;34(4):400\u20137.","journal-title":"J Autoimmun"},{"issue":"3","key":"2673_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrrheum.2016.217","volume":"13","author":"M Bombardieri","year":"2017","unstructured":"Bombardieri M, Lewis M, Pitzalis C. Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat Rev Rheumatol. 2017;13(3):141\u201354.","journal-title":"Nat Rev Rheumatol"},{"key":"2673_CR5","volume":"145","author":"F Barone","year":"2015","unstructured":"Barone F, Campos J, Bowman S, Fisher BA. The value of histopathological examination of salivary gland biopsies in diagnosis, prognosis and treatment of Sjogren's Syndrome. Swiss Med Wkly. 2015;145:w14168.","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"2673_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/jcp.21.5.656","volume":"21","author":"DM Chisholm","year":"1968","unstructured":"Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjogren's disease. J Clin Pathol. 1968;21(5):656\u201360.","journal-title":"J Clin Pathol"},{"key":"2673_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fimmu.2020.00601","volume":"11","author":"A Mohr","year":"2020","unstructured":"Mohr A, Tresallet C, Monot N, Bauvois A, Abiven D, Atif M, et al. Tissue infiltrating LTi-like group 3 innate lymphoid cells and T follicular helper cells in Graves' and Hashimoto's thyroiditis. Front Immunol. 2020;11:601.","journal-title":"Front Immunol"},{"key":"2673_CR8","first-page":"119","volume":"426","author":"F Rivellese","year":"2020","unstructured":"Rivellese F, Pontarini E, Pitzalis C. Tertiary lymphoid organs in rheumatoid arthritis. Curr Top Microbiol Immunol. 2020;426:119\u201341.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"27","key":"2673_CR9","doi-asserted-by":"publisher","first-page":"13490","DOI":"10.1073\/pnas.1905301116","volume":"116","author":"S Nayar","year":"2019","unstructured":"Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, et al. Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc Natl Acad Sci U S A. 2019;116(27):13490\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2673_CR10","first-page":"9","volume":"2018","author":"E Pipi","year":"1952","unstructured":"Pipi E, Nayar S, Gardner DH, Colafrancesco S, Smith C, Barone F. Tertiary lymphoid structures: autoimmunity goes local. Front Immunol. 1952;2018:9.","journal-title":"Front Immunol"},{"key":"2673_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102590","volume":"117","author":"B Wang","year":"2020","unstructured":"Wang B, Chen S, Zheng Q, Li Y, Zhang X, Xuan J, et al. Early diagnosis and treatment for Sjogren's syndrome: current challenges, redefined disease stages and future prospects. J Autoimmun. 2020;117:102590.","journal-title":"J Autoimmun"},{"issue":"3","key":"2673_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1399-0039.2005.00434.x","volume":"66","author":"MU Norman","year":"2005","unstructured":"Norman MU, Hickey MJ. Mechanisms of lymphocyte migration in autoimmune disease. Tissue Antigens. 2005;66(3):163\u201372.","journal-title":"Tissue Antigens"},{"issue":"50","key":"2673_CR13","doi-asserted-by":"publisher","first-page":"52487","DOI":"10.1074\/jbc.M406512200","volume":"279","author":"ML Allende","year":"2004","unstructured":"Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279(50):52487\u201392.","journal-title":"J Biol Chem"},{"issue":"1","key":"2673_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","volume":"115","author":"V Brinkmann","year":"2007","unstructured":"Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115(1):84\u2013105.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"2673_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/ni1083","volume":"5","author":"G Cinamon","year":"2004","unstructured":"Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol. 2004;5(7):713\u201320.","journal-title":"Nat Immunol"},{"key":"2673_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.immunol.23.021704.115628","volume":"23","author":"JG Cyster","year":"2005","unstructured":"Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127\u201359.","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"2673_CR17","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1084\/jem.20062446","volume":"204","author":"J Kunisawa","year":"2007","unstructured":"Kunisawa J, Kurashima Y, Higuchi M, Gohda M, Ishikawa I, Ogahara I, et al. Sphingosine 1-phosphate dependence in the regulation of lymphocyte trafficking to the gut epithelium. J Exp Med. 2007;204(10):2335\u201348.","journal-title":"J Exp Med"},{"issue":"2","key":"2673_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1084\/jem.20041509","volume":"201","author":"CG Lo","year":"2005","unstructured":"Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 2005;201(2):291\u2013301.","journal-title":"J Exp Med"},{"issue":"6972","key":"2673_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355\u201360.","journal-title":"Nature"},{"issue":"1","key":"2673_CR20","first-page":"11","volume":"3","author":"K Chiba","year":"2006","unstructured":"Chiba K, Matsuyuki H, Maeda Y, Sugahara K. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol. 2006;3(1):11\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"2673_CR21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s40265-014-0264-y","volume":"74","author":"M Sanford","year":"2014","unstructured":"Sanford M. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis. Drugs. 2014;74(12):1411\u201333.","journal-title":"Drugs"},{"issue":"3","key":"2673_CR22","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.4049\/jimmunol.180.3.1921","volume":"180","author":"M Sekiguchi","year":"2008","unstructured":"Sekiguchi M, Iwasaki T, Kitano M, Kuno H, Hashimoto N, Kawahito Y, et al. Role of sphingosine 1-phosphate in the pathogenesis of Sjogren's syndrome. J Immunol. 2008;180(3):1921\u20138.","journal-title":"J Immunol"},{"key":"2673_CR23","doi-asserted-by":"publisher","unstructured":"Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, et al. Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.\u00a0Pharmacol Res Perspect. 2017;5(6):e00370. https:\/\/doi.org\/10.1002\/prp2.370.","DOI":"10.1002\/prp2.370"},{"issue":"7","key":"2673_CR24","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.4049\/jimmunol.1201216","volume":"189","author":"M Bombardieri","year":"2012","unstructured":"Bombardieri M, Barone F, Lucchesi D, Nayar S, van den Berg WB, Proctor G, et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL\/6 mice. J Immunol. 2012;189(7):3767\u201376.","journal-title":"J Immunol"},{"issue":"4","key":"2673_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/1744666X.2014.883920","volume":"10","author":"A Donate","year":"2014","unstructured":"Donate A, Voigt A, Nguyen CQ. The value of animal models to study immunopathology of primary human Sjogren's syndrome symptoms. Expert Rev Clin Immunol. 2014;10(4):469\u201381.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2673_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3899\/jrheum.190820","volume":"47","author":"M Killian","year":"2020","unstructured":"Killian M, Batteux F, Paul S. The MRL\/lpr mouse model: an important animal model for systemic Sjogren syndrome and polyautoimmunity. J Rheumatol. 2020;47(1):157.","journal-title":"J Rheumatol"},{"key":"2673_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-015-0798-8","volume":"17","author":"M Sato","year":"2015","unstructured":"Sato M, Kuroda S, Mansjur KQ, Khaliunaa G, Nagata K, Horiuchi S, et al. Low-intensity pulsed ultrasound rescues insufficient salivary secretion in autoimmune sialadenitis. Arthritis Res Ther. 2015;17:278.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2673_CR28","first-page":"925","volume":"42","author":"D Zoukhri","year":"2001","unstructured":"Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjogren's syndrome. Invest Ophthalmol Vis Sci. 2001;42(5):925\u201332.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2673_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1746-1596-9-5","volume":"9","author":"X Ma","year":"2014","unstructured":"Ma X, Zou J, He L, Zhang Y. Dry eye management in a Sjogren's syndrome mouse model by inhibition of p38-MAPK pathway. Diagn Pathol. 2014;9:5.","journal-title":"Diagn Pathol"},{"issue":"1","key":"2673_CR30","first-page":"9","volume":"83","author":"M Wahren","year":"1994","unstructured":"Wahren M, Skarstein K, Blange I, Pettersson I, Jonsson R. MRL\/lpr mice produce anti-Ro 52,000 MW antibodies: detection, analysis of specificity and site of production. Immunology. 1994;83(1):9\u201315.","journal-title":"Immunology"},{"key":"2673_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-1-4939-6931-9_16","volume":"1591","author":"S Nayar","year":"2017","unstructured":"Nayar S, Campos J, Steinthal N, Barone F. Tissue digestion for stromal cell and leukocyte isolation. Methods Mol Biol. 2017;1591:225\u201334.","journal-title":"Methods Mol Biol"},{"issue":"35","key":"2673_CR32","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1073\/pnas.1503315112","volume":"112","author":"F Barone","year":"2015","unstructured":"Barone F, Nayar S, Campos J, Cloake T, Withers DR, Toellner KM, et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc Natl Acad Sci U S A. 2015;112(35):11024\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2673_CR33","doi-asserted-by":"publisher","first-page":"e0193236","DOI":"10.1371\/journal.pone.0193236","volume":"13","author":"KR Taylor Meadows","year":"2018","unstructured":"Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, et al. Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS One. 2018;13(4):e0193236.","journal-title":"PLoS One"},{"key":"2673_CR34","doi-asserted-by":"crossref","unstructured":"Strasser DS, Froidevaux S, Sippel V, Gerossier E, Grieder U, Pierlot GM, et al. Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. RMD Open. 2020;6(2).","DOI":"10.1136\/rmdopen-2020-001261"},{"issue":"2","key":"2673_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/sj.gene.6364286","volume":"7","author":"J Liu","year":"2006","unstructured":"Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, Gilkeson GS, et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun. 2006;7(2):156\u201368.","journal-title":"Genes Immun"},{"key":"2673_CR36","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3389\/fimmu.2020.01569","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu L, Takeda K, Akkoyunlu M. Disease stage-specific pathogenicity of CD138 (Syndecan 1)-expressing T cells in systemic lupus erythematosus. Front Immunol. 2020;11:1569.","journal-title":"Front Immunol"},{"issue":"8 Suppl 3","key":"2673_CR37","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1212\/WNL.0b013e31820d9596","volume":"76","author":"DD Pinschewer","year":"2011","unstructured":"Pinschewer DD, Brinkmann V, Merkler D. Impact of sphingosine 1-phosphate modulation on immune outcomes. Neurology. 2011;76(8 Suppl 3):S15\u20139.","journal-title":"Neurology"},{"issue":"5","key":"2673_CR38","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1172\/JCI3234","volume":"102","author":"DI Stott","year":"1998","unstructured":"Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest. 1998;102(5):938\u201346.","journal-title":"J Clin Invest"},{"issue":"7","key":"2673_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nri3700","volume":"14","author":"C Pitzalis","year":"2014","unstructured":"Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 2014;14(7):447\u201362.","journal-title":"Nat Rev Immunol"},{"key":"2673_CR40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fimmu.2016.00430","volume":"7","author":"E Corsiero","year":"2016","unstructured":"Corsiero E, Nerviani A, Bombardieri M, Pitzalis C. Ectopic Lymphoid Structures: Powerhouse of Autoimmunity. Front Immunol. 2016;7:430.","journal-title":"Front Immunol"},{"key":"2673_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102549","volume":"115","author":"PL Cohen","year":"2020","unstructured":"Cohen PL, McCulloch A. Fingolimod reduces salivary infiltrates and increases salivary secretion in a murine Sjogren's model. J Autoimmun. 2020;115:102549.","journal-title":"J Autoimmun"},{"issue":"1","key":"2673_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/mi.2017.37","volume":"11","author":"CA Huppe","year":"2018","unstructured":"Huppe CA, Blais Lecours P, Lechasseur A, Gendron DR, Lemay AM, Bissonnette EY, et al. A sphingosine-1-phosphate receptor 1 agonist inhibits tertiary lymphoid tissue reactivation and hypersensitivity in the lung. Mucosal Immunol. 2018;11(1):112\u20139.","journal-title":"Mucosal Immunol"},{"issue":"9","key":"2673_CR43","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/ni829","volume":"3","author":"MB Litinskiy","year":"2002","unstructured":"Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3(9):822\u20139.","journal-title":"Nat Immunol"},{"issue":"2","key":"2673_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/annrheumdis-2017-212619","volume":"78","author":"S Nayar","year":"2019","unstructured":"Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S, et al. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjogren's syndrome. Ann Rheum Dis. 2019;78(2):249\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2673_CR45","first-page":"935","volume":"27","author":"S Perrier","year":"2000","unstructured":"Perrier S, Serre AF, Dubost JJ, Beaujon G, Plazonnet MP, Albuisson E, et al. Increased serum levels of interleukin 10 in Sjogren's syndrome; correlation with increased IgG1. J Rheumatol. 2000;27(4):935\u20139.","journal-title":"J Rheumatol"},{"issue":"3","key":"2673_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10238-004-0049-9","volume":"4","author":"R Bertorello","year":"2004","unstructured":"Bertorello R, Cordone MP, Contini P, Rossi P, Indiveri F, Puppo F, et al. Increased levels of interleukin-10 in saliva of Sjogren's syndrome patients. Correlation with disease activity. Clin Exp Med. 2004;4(3):148\u201351.","journal-title":"Clin Exp Med"},{"issue":"5","key":"2673_CR47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T Dorner","year":"2019","unstructured":"Dorner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, et al. Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78(5):641\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2673_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/rheumatology\/kez255","volume":"59","author":"S Colafrancesco","year":"2020","unstructured":"Colafrancesco S, Priori R, Smith CG, Minniti A, Iannizzotto V, Pipi E, et al. CXCL13 as biomarker for histological involvement in Sjogren's syndrome. Rheumatology (Oxford). 2020;59(1):165\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2673_CR49","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.4049\/jimmunol.0803588","volume":"182","author":"L Le Pottier","year":"2009","unstructured":"Le Pottier L, Devauchelle V, Fautrel A, Daridon C, Saraux A, Youinou P, et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol. 2009;182(6):3540\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"2673_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jdsr.2019.09.006","volume":"55","author":"HM Ibrahem","year":"2019","unstructured":"Ibrahem HM. B cell dysregulation in primary Sjogren's syndrome: a review. Jpn Dent Sci Rev. 2019;55(1):139\u201344.","journal-title":"Jpn Dent Sci Rev"},{"issue":"1","key":"2673_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sjogren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017;69(1):35\u201345.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2673_CR52","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/08916934.2017.1280027","volume":"50","author":"AR Rodrigues","year":"2017","unstructured":"Rodrigues AR, Soares R. Inflammation in Sjogren's syndrome: cause or consequence? Autoimmunity. 2017;50(3):141\u201350.","journal-title":"Autoimmunity"},{"issue":"6","key":"2673_CR53","first-page":"1089","volume":"24","author":"MM Grisius","year":"1997","unstructured":"Grisius MM, Bermudez DK, Fox PC. Salivary and serum interleukin 6 in primary Sjogren's syndrome. J Rheumatol. 1997;24(6):1089\u201391.","journal-title":"J Rheumatol"},{"issue":"9","key":"2673_CR54","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/rheumatology\/keq121","volume":"49","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Scofield RH, Hyon JY, Yun PY, Lee HJ, Lee EY, et al. Salivary chemokine levels in patients with primary Sjogren's syndrome. Rheumatology (Oxford). 2010;49(9):1747\u201352.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2673_CR55","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1002\/art.10577","volume":"46","author":"N Ogawa","year":"2002","unstructured":"Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum. 2002;46(10):2730\u201341.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2673_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/rheumatology\/37.7.779","volume":"37","author":"C Cuello","year":"1998","unstructured":"Cuello C, Palladinetti P, Tedla N, Di Girolamo N, Lloyd AR, McCluskey PJ, et al. Chemokine expression and leucocyte infiltration in Sjogren's syndrome. Br J Rheumatol. 1998;37(7):779\u201383.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"2673_CR57","first-page":"970","volume":"29","author":"EH Kang","year":"2011","unstructured":"Kang EH, Lee YJ, Hyon JY, Yun PY, Song YW. Salivary cytokine profiles in primary Sjogren's syndrome differ from those in non-Sjogren sicca in terms of TNF-alpha levels and Th-1\/Th-2 ratios. Clin Exp Rheumatol. 2011;29(6):970\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2673_CR58","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.1038\/s41598-019-43714-5","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Aqrawi LA, Utheim TP, Tashbayev B, Utheim OA, Reppe S, et al. Elevated cytokine levels in tears and saliva of patients with primary Sjogren's syndrome correlate with clinical ocular and oral manifestations. Sci Rep. 2019;9(1):7319.","journal-title":"Sci Rep"},{"issue":"7","key":"2673_CR59","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/rheumatology\/ker019","volume":"50","author":"G Hernandez-Molina","year":"2011","unstructured":"Hernandez-Molina G, Michel-Peregrina M, Hernandez-Ramirez DF, Sanchez-Guerrero J, Llorente L. Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases. Rheumatology (Oxford). 2011;50(7):1288\u201392.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2673_CR60","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/ard.62.4.359","volume":"62","author":"P Willeke","year":"2003","unstructured":"Willeke P, Schotte H, Schluter B, Erren M, Becker H, Dyong A, et al. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis. 2003;62(4):359\u201362.","journal-title":"Ann Rheum Dis"},{"key":"2673_CR61","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clim.2017.04.003","volume":"182","author":"J Kiripolsky","year":"2017","unstructured":"Kiripolsky J, McCabe LG, Kramer JM. Innate immunity in Sjogren's syndrome. Clin Immunol. 2017;182:4\u201313.","journal-title":"Clin Immunol"},{"issue":"1","key":"2673_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1573397112666160714164149","volume":"13","author":"P Sandhya","year":"2017","unstructured":"Sandhya P, Kurien BT, Danda D, Scofield RH. Update on Pathogenesis of Sjogren's Syndrome. Curr Rheumatol Rev. 2017;13(1):5\u201322.","journal-title":"Curr Rheumatol Rev"},{"issue":"6","key":"2673_CR63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/1759720X10381431","volume":"2","author":"M Voulgarelis","year":"2010","unstructured":"Voulgarelis M, Tzioufas AG. Current aspects of pathogenesis in Sjogren's syndrome. Ther Adv Musculoskelet Dis. 2010;2(6):325\u201334.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"2673_CR64","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/labinvest.3780062","volume":"80","author":"SC van Blokland","year":"2000","unstructured":"van Blokland SC, van Helden-Meeuwsen CG, Wierenga-Wolf AF, Drexhage HA, Hooijkaas H, van de Merwe JP, et al. Two different types of sialoadenitis in the NOD- and MRL\/lpr mouse models for Sjogren's syndrome: a differential role for dendritic cells in the initiation of sialoadenitis? Lab Invest. 2000;80(4):575\u201385.","journal-title":"Lab Invest"},{"key":"2673_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/OARRR.S167783","volume":"11","author":"SG Pasoto","year":"2019","unstructured":"Pasoto SG. Adriano de Oliveira Martins V, Bonfa E: Sjogren's syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol. 2019;11:33\u201345.","journal-title":"Open Access Rheumatol"},{"issue":"1","key":"2673_CR66","doi-asserted-by":"publisher","first-page":"e000354","DOI":"10.1136\/lupus-2019-000354","volume":"6","author":"V Hermann","year":"2019","unstructured":"Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019;6(1):e000354.","journal-title":"Lupus Sci Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02673-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02673-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02673-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:13:12Z","timestamp":1675987992000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02673-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2673"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02673-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were conducted in accordance with the Swiss Animal Welfare Ordinance and Idorsia Animal Welfare Policy on the use of experimental animals, and in accordance with the University of Birmingham, Home Office, and local ethics committee regulations. The study was approved by the Baselland Cantonal Veterinary Home Office or the Home Office, UK (PPL# P4B291FAA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EG, EV, GP, UM, MJM and MMM are employees of Idorsia Pharmaceuticals Ltd. SN received Grant\/Research support from Idorsia Pharmaceuticals Ltd; FB received Grant\/Research support from ARUK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}